Chimerix hires a Chief Development Officer

Michael Rogers joins the company from Pharmasset

Chimerix, a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, says Michael Rogers has joined the company as Chief Development Officer.

Rogers will be responsible for overseeing chemistry, manufacturing, toxicology and project management as well as the advancement of compounds from the Chimerix Chemical Library.

He was formerly Chief Development Officer at Pharmasset, a pioneer in the use of nucleotide analogs for the treatment of Hepatitis C virus (HCV), until its acquisition by Gilead Sciences in January 2012. During his five years at Pharmasset, he was responsible for development, regulatory and portfolio management activities.

Prior to joining Pharmasset, Rogers held several positions in antiviral discovery and development at GlaxoSmithKline, including serving as Vice President, Division of Viral Diseases. In addition, he has led numerous anti-infective projects that resulted in successful commercialisation.

You may also like

Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Regulatory

Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval

The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
Subscribe now